Which Mental Health Apps Are FDA-Approved?

FDA-approved mental health apps

Verywell / Laura Porter

In recent years, thousands of apps have been released to help people manage their mental health. These apps are designed for various issues, including stress, anxiety, sleep, and daily functioning. In addition, there is a whole category of apps specifically to help autistic people communicate and address sensory issues.

Although an increase in telehealth has significantly improved access to care for many Americans, a shortage of qualified professionals makes it difficult for people to get the services they need.

While no app is a substitute for therapy services, apps can supplement therapy and offer additional support.

The Food and Drug Administration (FDA) is the federal agency responsible for protecting public health by regulating food safety, medications, manufacturing, medical devices, and many other industries. Anyone with sufficient knowledge of coding can release an app, so the FDA has begun offering an approval process for these apps to demonstrate their effectiveness.

How Does the FDA Approve Apps?

According to the FDA’s website, “The FDA encourages the development of mobile medical apps (MMAs) that improve health care and provide consumers and health care professionals with valuable health information. The FDA also has a public health responsibility to oversee the safety and effectiveness of medical devices—including mobile medical apps.”

Essentially, technology has allowed access to resources for health and wellness that were never possible before. At the same time, though, anyone can create an app. The FDA’s role is to ensure that these apps do what they claim to do, provide support based on evidence, and benefit the people using them.

The FDA regulates apps that function as medical devices, so if an app merely provides education about mental health, it is not eligible for FDA approval. However, if an app provides a therapeutic intervention (for example), the creators might seek FDA approval to certify their app.

It can take years for an app to be approved, and the FDA might approve a specific function of the app rather than the app in its entirety.

What Does It Mean If an App Is FDA-Approved?

If an app is FDA-approved, this means that the developers went through the process of requesting this approval and demonstrated that their app meets the criteria for software as a medical device.

For the software to be considered a medical device, it must be “intended to be used for one or more medical purposes that perform these purposes without being part of a hardware medical device.”

The FDA thoroughly vets apps before approving them, and it has high standards to provide this approval. Typically, an app that receives FDA approval will require a prescription and be used in conjunction with therapy or other treatment services.

Which Apps Are FDA-Approved?

As of November 2024, the FDA has approved six mental health apps, listed below.

Rejoyn

Rejoyn is the first FDA-approved app to treat depression, including major depressive disorder (MDD). It was designed specifically for people age 22 and older who need depression support and treatment beyond just their antidepressant. This app is meant to be used in conjunction with medication and outpatient treatment.

Approved in April of 2024, a prescription is required in order to sign up and use Rejoyn. Along with short, 3- to 4-minute cognitive behavioral therapy (CBT) exercises and lessons, Rejoyn is unique in focusing on improving working memory in those with MDD, the deficits of which are thought to be connected to significant MDD symptoms.

Rejoyn was FDA-approved after a clinical trial including over 350 adults who had not experienced a remission of depression symptoms on their antidepressant alone. After six weeks of using this app, users scored much lower on standard depression scale ratings, indicating that Rejoyn is a helpful resource in the compound treatment of depression.

EndeavorRx

EndeavorRx is a video game designed to treat ADHD in children ages 8-17 and received FDA approval in 2020. To subscribe to the app, you must have a prescription from a healthcare provider that verifies your diagnosis and the need for treatment. The app uses a science fiction backdrop to practice focus and attention using an evidence-based protocol.

The app is designed to be played for 25 minutes a day, five days a week, for at least four consecutive weeks in order to improve attention; a 30-day prescription costs $99. The game provides fun but challenging activities that teach the player to sustain attention, prioritize and selectively focus, and attend to multiple stimuli at a time.

EndeavorRx is the first-ever video game to receive FDA approval to treat attention-deficit/hyperactivity disorder (ADHD). Before receiving approval, the creators of EndeavorRx completed four peer-reviewed studies to show that the game effectively improves ADHD symptoms.

NightWare

NightWare advertises as a treatment for “nightmare disorder” or nightmares caused by post-traumatic stress disorder (PTSD). It is a digital watch that uses software to monitor physiological experiences while the wearer is asleep.

It is not available on any app store and requires a prescription from a healthcare provider.

Clients wear the device (an Apple Watch), which senses nightmares or disturbing dreams and uses vibration to wake the client and end the dream. Research showed improvement in anxiety symptoms, reduced nightmares, and overall improved sleep quality when wearing the NightWare device.

NightWare was approved as a treatment for nightmares in 2020 in adults age 22 and older.

ReSET

When searching for the reSET app, multiple options appear. The FDA-approved PursueCare reSET app (previously owned by Pear, which filed for bankruptcy) is designed to treat substance use disorders (SUDs). It was developed to supplement outpatient treatment for alcohol, cocaine, marijuana, and stimulant abuse.

You need an access code provided by a healthcare professional in order to use reSET, and it uses a client and clinician dashboard to teach cognitive behavioral skills to support abstinence from the addictive substance. The app was shown to improve treatment outcomes when used in conjunction with outpatient SUD treatment.

This app is not approved for treating alcohol abuse in the absence of additional substance abuse, and it is not approved for opioid treatment.

ReSET-O

ReSET-O was created by the same minds behind reSET and was developed to expand the reSET app’s functions to include treatment for opioid use disorder. Like the reSET app, it uses tenets of cognitive behavioral therapy to help clients abstain from opioid use.

As with the original reSET app, reSET-O requires a prescription and is intended for collaborative use between clients and treatment providers. Unlike the reSET app, reSET-O did not have peer-reviewed research showing that it decreased opioid use in users at the time of approval. However, reSET-O users had a higher rate of retention in outpatient programs compared to those who did not use reSET-O to supplement their treatment.

The FDA granted approval for reSET-O through premarket registration.

Somryst

Somryst is an app designed to train the brain to get higher-quality sleep, and it is FDA-approved for treating insomnia using cognitive behavioral therapy for insomnia (CBT-I). It is approved for use by individuals aged 22 and older who speak and read English, live in the United States, and are able to use the app. Somryst requires that users be under the care of a medical provider.

Somryst uses six lessons based in CBT-I that individuals can complete at their own pace over the course of nine weeks. It provides specific instructions based on evidence-based treatment for insomnia to help clients sleep better.

Somryst was recently acquired by Nox Health, which is currently working on adding the app to its available sleep-centric services.

What Does This Mean for the Mental Health Field?

These apps can provide support and symptom management for clients in between sessions, hoping to reinforce work done in therapy. Some, like Nightware, provide a therapeutic intervention that a traditional therapist cannot do.

By regulating mental health apps, the FDA is implementing standards for these kinds of resources. This ensures that users know the risks and benefits of the apps and can rely on an evidence base for these claims. In addition, providers can make confident recommendations knowing that the FDA vetted these resources first.

If you feel that an app discussed in this article would benefit your treatment, talk to your healthcare provider(s) about your options.

12 Sources
Verywell Mind uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Hoffman DA. Increasing access to care: telehealth during COVID-19J Law Biosci. 2020;7(1):lsaa043. doi:10.1093/jlb/lsaa043

  2. Food and Drug Administration. Policy for device software functions and mobile medical applications: guidance for industry and Food and Drug Administration staff.

  3. International Medical Device Regulators Forum. Software as a Medical Device (SaMD): key definitions.

  4. Pivotal clinical trial results. Clinical data: Rejoyn helped reduce symptoms of MDD. (n.d.). https://www.rejoynhcp.com/clinical-data

  5. Canady VA. FDA approves first video game Rx treatment for children with ADHDMent Health Wkly. 2020;30(26):1-7. doi:10.1002/mhw.32423

  6. Anderson M. Prescription-strength gaming: ADHD treatment now comes in the form of a first-person racing game - [news]IEEE Spectr. 2020;57(8):9-10. doi:10.1109/MSPEC.2020.9150542

  7. NightWare. A modern option for your patients.

  8. Food and Drug Administration. FDA permits marketing of new device designed to reduce sleep disturbance related to nightmares in certain adults.

  9. Food and Drug Administration. FDA permits marketing of mobile medical application for substance use disorder.

  10. Pear Therapeutics. Clinical evidence.

  11. Food and Drug Administration. FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs.

  12. Morin CM. Profile of Somryst prescription digital therapeutic for chronic insomnia: overview of safety and efficacyExpert Rev Med Devices. 2020;17(12):1239-1248. doi:10.1080/17434440.2020.1852929

Headshot of Amy Marschall

By Amy Marschall, PsyD
Dr. Amy Marschall is an autistic clinical psychologist with ADHD, working with children and adolescents who also identify with these neurotypes among others. She is certified in TF-CBT and telemental health.

Updated by
Hannah Owens, LMSW
ho

Hannah Owens is the Mental Health/General Health Editor for Dotdash Meredith. She is a licensed social worker with clinical experience in community mental health.

Learn about our editorial process